Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay

American Journal of Clinical Pathology

Volumn 136, Issue 5, 2011, Pages 696-704

  Martins, Thomas B ^a   Rose, John W ^b,c   Jaskowski, Troy D ^a   Wilson, Andrew R ^a   Husebye, Dee ^c   Seraj, Hanieh S ^c   Hill, Harry R ^a,c  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b Department of Neurology ^*  (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Multiple sclerosis; Multiplexed assay

Indexed keywords

BETA INTERFERON; CD40 LIGAND; CYTOKINE; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLEXED FLUORESCENT MICROSPHERE IMMUNOASSAY; PRIORITY JOURNAL; RELAPSE;

ADULT; AGED; CYTOKINES; FEMALE; HUMANS; IMMUNOASSAY; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 80355125745     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP7UBK8IBVMVNR     Document Type: Article

References (32)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907-911.
2. Martins TB, Anderson JL, Muhlestein JB, et al. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol. 2006;125:906-913. (Pubitemid 43801541)
3. Martins TB, Pasi BM, Litwin CM, et al. Heterophile antibody interference in a multiplexed fluorescent microsphere immunoassay for quantitation of cytokines in human serum. Clin Diagn Lab Immunol. 2004;11:325-329. (Pubitemid 38380813)
4. Rose JW, Carlson NG. Clinical biomarkers in multiple sclerosis. Expert Opin Med Diagn. 2011;5:213-226.
5. Brettschneider J, Jaskowski TD, Tumani H, et al. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol. 2009;217:95-101.
6. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
7. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol. 2005;58:840-846. (Pubitemid 41746873)
8. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121-127.
9. Fulton RJ, McDade RL, Smith PL, et al. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem. 1997;43:1749-1756.
10. Martins TB, Pasi BM, Pickering JW, et al. Determination of cytokine responses using a multiplexed fluorescent microsphere immunoassay. Am J Clin Pathol. 2002;118:346-353. (Pubitemid 37046332)
11. Staros JV, Wright RW, Swingle DM. Enhancement by N- hydroxysulfosuccinimide of water-soluble carbodiimidemediated coupling reactions. Anal Biochem. 1986;156:220-222. (Pubitemid 16044423)
12. Panitch HS, Hirsch RL, Schindler J, et al. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37:1097-1102. (Pubitemid 17123439)
13. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol. 1993;46:145-153.
14. Graber JJ, Ford D, Zhan M, et al. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol. 2007;185:168-174. (Pubitemid 46497443)
15. Sharief MK, Thompson EJ. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993;56:169-174. (Pubitemid 23075411)
16. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995;37:424-435.
17. Takahashi JL, Giuliani F, Power C, et al. Interleukin- 1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol. 2003;53:588-595. (Pubitemid 36529432)
18. Claudio L, Martiney JA, Brosnan CF. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha. Lab Invest. 1994;70:850-861. (Pubitemid 24209486)
19. Duchini A, Govindarajan S, Santucci M, et al. Effects of tumor necrosis factor-alpha and interleukin-6 on fluidphase permeability and ammonia diffusion in CNS-derived endothelial cells. J Investig Med. 1996;44:474-482. (Pubitemid 126820697)
20. Hartung HP, Jung S, Stoll G, et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol. 1992;40:197-210.
21. Ledeen RW, Chakraborty G. Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis. Neurochem Res. 1998;23:277-289. (Pubitemid 28109873)
22. Karpus WJ, Gould KE, Swanborg RH. CD4+ suppressor cells of autoimmune encephalomyelitis respond to T cell receptor-associated determinants on effector cells by interleukin-4 secretion. Eur J Immunol. 1992;22:1757-1763.
23. H2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J Exp Med. 1997;185:901-907.
24. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med. 1994;180:1961-1966. (Pubitemid 24328587)
25. Cash E, Minty A, Ferrara P, et al. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J Immunol. 1994;153:4258-4267. (Pubitemid 24322593)
26. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain. 2004;127:1463-1478. (Pubitemid 38899400)
27. Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis [published online ahead of print April 3, 2011]. J Neurol Sci. 2011;305:1-10. doi:10.1016/j.jns.2011.03.026.
28. Martin R, Bielekova B, Hohlfeld R, et al. Biomarkers in multiple sclerosis. Dis Markers. 2006;22:183-185. (Pubitemid 44763271)
29. Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther. 2005;106:163-177. (Pubitemid 40603863)
30. Hagman S, Raunio M, Rossi M, et al. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J Neuroimmunol. 2011;234:141-147.
31. H2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Eur Neurol. 2011;65:164-169.
32. Kraus J, Kuehne BS, Tofighi J, et al. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis. Acta Neurol Scand. 2002;105:300-308. (Pubitemid 34407234)